Skip to main content
. 2021 Jun 25;17(3):240–247. doi: 10.4244/EIJ-D-20-00749

Figure 2.

Figure 2

Distribution of ARC-HBR criteria in the pooled LEADERS FREE and LEADERS FREE II studies. ARC-HBR: Academic Research Consortium High Bleeding Risk; BMS: bare metal stent; CKD: chronic kidney disease; DAPT: dual antiplatelet therapy; DCS: drug-coated stent; eGFR: estimated glomerular filtration rate; ICH: intracranial haemorrhage; LF: LEADERS FREE; NSAIDs: non-steroidal anti-inflammatory drugs